Literature DB >> 1909635

Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases.

S P Robins1, D Black, C R Paterson, D M Reid, A Duncan, M J Seibel.   

Abstract

Analyses of the urinary concentration relative to creatinine of the collagen crosslinks, pyridinoline (Pyd) and deoxy-pyridinoline (Dpd) were made in 47 patients with metabolic bone diseases to assess the validity of these assays as indicators of bone resorption. The mean values for patients with Paget's disease of bone, primary hyperparathyroidism and osteomalacia were significantly higher (P less than 0.001) than those for age-matched healthy individuals. During treatment of Paget's disease with bisphosphonates, there was a steady decline in the urinary concentration of the crosslinks to the normal range; this change occurred earlier than for serum alkaline phosphatase. There were significant correlations (P less than 0.01) between the concentrations of both crosslinks and the corresponding values for hydroxyproline. At lower crosslink concentrations, however, these relationships were less marked due to large variations in hydroxyproline values. The results show that measurements of urinary Pyd and Dpd provide clinically applicable indices of bone resorption that are more specific than other markers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909635     DOI: 10.1111/j.1365-2362.1991.tb01375.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  31 in total

Review 1.  Osteoporosis: whose problem is it?

Authors:  A D Woolf
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

2.  Seasonal differences in biochemical parameters of bone remodelling.

Authors:  A S Douglas; M H Miller; D M Reid; J D Hutchison; R W Porter; S P Robins
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

3.  High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K.

Authors:  A F Schilling; C Mülhausen; W Lehmann; R Santer; T Schinke; J M Rueger; M Amling
Journal:  Osteoporos Int       Date:  2007-01-06       Impact factor: 4.507

4.  The effect of cyclosporin A administration on bone metabolism in the rat evaluated by biochemical markers.

Authors:  K Kawana; M Takahashi; K Kushida; H Hoshino; S Sakata; T Inoue
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

Review 5.  Corticosteroid-sparing options in the treatment of childhood asthma.

Authors:  P J Helms
Journal:  Drugs       Date:  2000       Impact factor: 9.546

6.  Bone resorption in syndromes of the Ras/MAPK pathway.

Authors:  D A Stevenson; E L Schwarz; J C Carey; D H Viskochil; H Hanson; S Bauer; H-Y Cindy Weng; T Greene; K Reinker; J Swensen; R J Chan; F-C Yang; L Senbanjo; Z Yang; R Mao; M Pasquali
Journal:  Clin Genet       Date:  2011-01-19       Impact factor: 4.438

7.  Fhl2 deficiency results in osteopenia due to decreased activity of osteoblasts.

Authors:  Thomas Günther; Cecilia Poli; Judith M Müller; Philip Catala-Lehnen; Thorsten Schinke; Na Yin; Sandra Vomstein; Michael Amling; Roland Schüle
Journal:  EMBO J       Date:  2005-08-04       Impact factor: 11.598

8.  Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis.

Authors:  L Sinigaglia; M Varenna; L Binelli; F Bartucci; M Arrigoni; R Ferrara; G Abbiati
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

9.  Bone mineral density and markers of bone turnover in patients with glycogen storage disease types I, III and IX.

Authors:  J Cabrera-Abreu; N J Crabtree; E Elias; W Fraser; R Cramb; S Alger
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

10.  Effect of polymyxin B-immobilized fiber on bone resorption in patients with sepsis.

Authors:  Tsukasa Nakamura; Yasuhiro Kawagoe; Takaharu Matsuda; Hikaru Koide
Journal:  Intensive Care Med       Date:  2004-06-12       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.